Lilly Offloads Verzenios in China | Raleigh News

Raleigh News Today | 2 Min News | The Daily News Now! · Jul 5, 2026 · 2m

Eli Lilly is quietly reshaping its China strategy by handing over commercial control of its breast cancer drug Verzenios to Innovent Biologics, while keeping manufacturing and R&D in-house — a move that lets Lilly cash in on China’s big reimbursement list while dodging political heat and generic competition. With Verzenios protected until 2029 and Lilly’s focus squarely on blockbuster weight-loss drugs like Zepbound and Mounjaro, this partnership is less about massive revenue shifts and more about smart operational streamlining — positioning Lilly to win the future without getting bogged down…